[1] 中华医学会传染病与寄生虫病分会, 中华医学会肝病学分会. 丙型肝炎防治指南. 中华肝脏病杂志, 2004,12: 194-198.
[2] 中华医学会传染病与寄生虫病分会, 中华医学会肝病学分会. 病毒性肝炎防治方案. 中华肝脏病杂志, 2000, 8: 324-329.
[3] Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis, 2005, 9: 383-398.
[4] Seeff LB. The history of the“natural history”of hepatitis C (1968－2009).Liver Int, 2009, 29 Suppl 1 : 89-99.
[5] Sherman KE. Advanced liver disease: what every hepatitis C virus treater should know. Top Antivir Med, 2011, 19: 121-125.
[6] 陈文, 王鲁文, 袁念芳, 等. 小剂量α-IFN治疗失代偿期丙型肝炎肝硬化的疗效观察. 实用肝脏病杂志, 2008, 11: 174-175.
[7] 李冰, 陈国凤, 韩萍, 等. 聚乙二醇干扰素α-2a联合利巴韦林治疗丙型肝炎肝硬化代偿期患者的疗效与安全性分析. 解放军药学学报, 2011, 27: 496-498.
[8] European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol, 2015, 63:199-236. |
